top of page

Cure CMD welcomes three new board members

Updated: Oct 27, 2021

Cure CMD welcomed three new members to the Board of Directors in July 2017. With the addition of Dr. Carla Grossman, Dr. Oscar H. Mayer, and Dr. Jodi Wolff, the board now has now deepened the number of directors participating from the medical and pharmaceutical community.

Carla Grosmann, MD

Dr. Grosmann is a neurologist at Rady Children's Hospital in San Diego, and is a clinical professor at the University of California San Diego (UCSD). She specializes in neuromuscular disorders and electrodiagnosis in children and adults, with a particular interest in undiagnosed muscular dystrophies and advocacy. Dr. Grossman participates on the Outreach Committee and serves as a physician advisor to the Congenital Muscle Disease International Registry (CMDIR).

Oscar H. Mayer, MD

Dr. Mayer is an expert in the assessment and treatment of neuromuscular disorders with an emphasis on the pulmonary manifestation in neuromuscular diseases. He is the Director of the Pulmonary Function Laboratory at the Children’s Hospital of Philadelphia. He also served as the co-principal investigator for the CMD Hyperinsufflation Trial, and continues to support and advocate for proactive pulmonary care for the CMD Community.

Jodi Wolff, PhD

Dr. Wolff is the Director of Patient Advocacy & Medical Science Liaison at Santhera Pharmaceuticals, where she promotes and facilitates patient engagement in the drug development process. She earned her PhD in Rehabilitation from the University of Arizona, focusing her research on the transition to adulthood for youth with neuromuscular disease. Dr. Wolff has worked with young people who have muscular dystrophy for over 20 years.

bottom of page